Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 2/20 | 0.43 |
| ▸ | EIF4E | P06730 | 3/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17066983 | 0.85 | MKNK1 (0.44) | MTORMKNK1MKNK2PDE4AKDM4E | |
| SCHEMBL15730516 | 0.83 | MKNK1 (0.61) | MTOREIF4EMKNK1MKNK2NPSR1 | |
| SCHEMBL14555831 | 0.81 | EIF4E (0.45) | EIF4EMKNK1MKNK2NPSR1RXFP1 | |
| SCHEMBL946824 | 0.79 | MKNK1 (0.41) | MKNK1MKNK2PDE4AKDM4EALDH1A1 | |
| SCHEMBL20371520 | 0.78 | MKNK1 (0.66) | MKNK1MKNK2PDE4A | |
| SCHEMBL17066990 | 0.78 | MTOR (0.56) | MTORHPGDCNR1PDK2 | |
| SCHEMBL17067051 | 0.77 | KMO (0.45) | PDE4A | |
| SCHEMBL1785281 | 0.76 | MKNK1 (0.47) | EIF4EMKNK1MKNK2NPSR1RXFP1 | |
| SCHEMBL353231 | 0.74 | KDM4E (0.55) | KDM4EALDH1A1HPGDHSD17B10P2RX7 | |
| SCHEMBL30011332 | 0.74 | KDM4E (0.55) | KDM4EALDH1A1HPGDHSD17B10P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370358-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180194746-A1 | Compounds For the Treatment of HIV | GILEAD SCIENCES, INC. | 2018-07-12 | — | — | US | disclosed |
| EP-2729448-B1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2015-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370358-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | MTOR 676/4885EIF4E 975/4885MKNK1 2159/4885 |
| US-20180194746-A1 | Compounds For the Treatment of HIV | CCR5, NPC1, FURIN | MTOR 676/4885EIF4E 975/4885MKNK1 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.